Physician profile
Janet E Weir
NPI 1447250824
$6,358.03
in general payments reported to CMS, 2019-2025
21 companies · $37.97 in 2025
The $37.97 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,787 · 2020: $201 · 2021: $1,200 · 2022: $674 · 2023: $125 · 2024: $333 · 2025: $37.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,300.84 | 2019 | |
| Glaxosmithkline, LLC. | $1,016.36 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $603.87 | 2019-2024 | Fasenra |
| Biocryst US Sales Co., LLC | $292.36 | 2021-2022 | |
| Csl Behring | $275.15 | 2019-2022 | |
| Genzyme Corporation | $125.38 | 2019-2022 | |
| Octapharma USA, INC. | $114.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.50 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.84 | 2021-2022 | |
| Genentech USA, INC. | $61.17 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $59.45 | 2021-2025 | |
| Kaleo, INC. | $55.36 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $51.15 | 2021 | |
| Adma Biomanufacturing LLC | $48.81 | 2021 | |
| Pfizer INC. | $37.76 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.97 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $24.99 | 2021 | |
| Aimmune Therapeutics, INC. | $17.89 | 2022 | |
| Blueprint Medicines Corporation | $13.87 | 2025 | Ayvakit |
| Circassia INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.